NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second cohort of its AXO-Lenti-PD program the morning of Tuesday, October 6, 2020. Additionally, as previously announced the Company will hold a Parkinsons Disease R&D Day on Friday, October 30. <\/p>\n
Information on the upcoming presentations can be found below:<\/p>\n
Chardan 4th Annual Genetic Medicines Conference<\/p>\n
2020 ARM Virtual Cell and Gene Meeting on the Mesa<\/p>\n
AXO-Lenti-PD Parkinsons Disease R&D Day <\/p>\n
A live webcast of the presentations will be available in the Events section of Axovant's website at http:\/\/www.axovant.com.Replays<\/a> will be available for approximately 30 days following the conferences.<\/p>\n About Axovant Gene Therapies<\/p>\n Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http:\/\/www.axovant.com<\/a>.<\/p>\n Contacts: <\/p>\n Media & Investors<\/p>\n Parag MeswaniAxovant Gene Therapies Ltd.(212) 547-2523media@axovant.cominvestors<\/a>@axovant.com<\/p>\n <\/p>\n See the original post here: <\/p>\n Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd Continue reading